1 2 3	TITLE:	Differences in bioprosthetic valve failure after aortic valve replacement in patients with immune mediated inflammatory diseases
4	AUTHORS	S: Christopher Sefton MD ¹ : Davis Leaphart MD ¹ : Benjamin Klein DO ¹ : Garrett
5 6	Santini, ME Roselli, ME	D ¹ ; Aditi Patel, MD ² ; M. Elaine Husni, MD ² MPH; Patrick R. Vargo, MD ³ ; Eric E. D ³ ; Lars Svensson, MD, PhD ³ ; Amar Krishnaswamy, MD ⁴ ; Samir Kapadia, MD ⁴ ;
7 8	Venu Meno	on, MD ⁴ ; Umesh Khot, MD ⁴ ; Heba Wassif, MD ⁴
9	¹ Internal M	ledicine Residency Program, Cleveland Clinic, Cleveland, OH
10	² Orthopedi	c and Rheumatological Institute, Department of Rheumatology, Cleveland Clinic,
11	Cleveland,	ОН
12	³ Heart, Vas	scular and Thoracic Institute, Department of Thoracic and Cardiovascular Surgery,
13	Cleveland C	Clinic, Cleveland, OH
14	⁴ Heart, Vas	scular and Thoracic Institute, Department of Cardiovascular Medicine, Cleveland
15	Clinic, Clev	veland, OH
16	,	
17		
18		
19	Word Cou	nt: 3578
20		
21		
22		
23		
24	Correspon	ding Author
25	Heba Wassi	if, MD, MPH
26	Department	t of Cardiology
27	Heart Vascu	ular Thoracic Institute
28	Cleveland C	Clinic Foundation
29	9500 Euclic	l Ave, J2
30	Cleveland,	OH 44195
31	wassifh@cc	<u>ef.org</u>
32		
33		
34	IRB Review	w: Study Number 23-095
35		
36		
37		
38		
39		
40		
41 42		
4Z		
45 11		
44 15		
40		

47 ABSTRACT

48

49 Introduction:

- 50 Immune-mediated inflammatory disease (IMID) is a subset of autoimmune diseases including
- 51 systemic lupus erythematosus, rheumatoid arthritis, and psoriasis that is emerging as a risk factor
- 52 for many cardiovascular diseases including valvular disease.
- 53

54 **Objectives:**

- 55 To determine whether IMID is associated with frequent and early development of bioprosthetic
- 56 valve failure (BVF) after surgical aortic valve replacement (SAVR) and transcatheter valve
- 57 replacement (TAVR).
- 58

59 Methods:

- 60 Serial echocardiograms for patients who underwent SAVR and TAVR at Cleveland Clinic
- between 2000 and 2022 were assessed for time to development of BVF after procedure. ICD10
- 62 codes were used to stratify to those with and without IMID. Kaplan-Meier curve and cox
- 63 proportional hazard regression analysis were used to assess for differences in development of
- 64 BVF after TAVR and SAVR.
- 65

66 **Results:**

- 67 351 TAVR patients (52 IMID and 299 controls) and 1961 SAVR patients (300 IMID and 1661
- 68 controls) were included. BVF after TAVR occurred in 12 (23.1%) IMID and 21 (7.0%) control
- 69 patients, respectively, yielding an adjusted hazard ratio of 4.02 (1.81 8.92). Time to 50% of
- 70 patients developing BVF was earlier among IMID, occurring at 6.6 years IMID and not reached
- in controls (p < 0.001). There were no significant differences in prevalence and time to
- 72 development of BVF in IMID vs controls after SAVR.
- 73

74 Conclusion:

- 75 After TAVR, BVF occurred earlier and more frequently in patients with IMID than controls.
- 76 This risk should be included during shared decision making among IMID patients considered for
- 77 TAVR, and may warrant more frequent monitoring post procedure. These differences in BVF
- 78 were not seen after SAVR.
- 79
- 80

- 82
- 83
- 84
- 85
- 86 87
- 88
- 89
- 90
- 91

- 92 Keywords: Bioprosthetic valve failure, transcatheter aortic valve replacement, surgical aortic
- 93 valve replacement, autoimmune disease, immune mediated inflammatory disease, aortic stenosis

95 Abbreviations:

- 96 IMID: immune mediated inflammatory disease
- 97 SLE: systemic lupus erythematosus
- 98 RA: Rheumatoid arthritis
- 99 CAD: Coronary artery disease
- 100 SAVR: surgical aortic valve replacement
- 101 TAVR: Transcatheter aortic valve replacement
- 102 BVF: bioprosthetic valve failure
- 103 AVR: Aortic valve replacement
- 104 MCTD: mixed connective tissue disease
- 105 DMARD: disease modifying antirheumatic drug

138 **INTRODUCTION:**

139 140 Immune mediated inflammatory diseases (IMID), including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and psoriasis among others¹, are emerging as 141 significant risk factors for development of early and accelerated cardiovascular disease^{2,3,4,5}. 142 143 Notable examples include increased incidence of cardiovascular disease and cardiovascular deaths in SLE patients⁶, and RA with similar risk for developing coronary artery disease (CAD) 144 145 as diabetes mellitus⁷. Furthermore, a recent population-based study found increased incidence of 146 nearly every cardiovascular disease, including CAD, atrial fibrillation, heart failure, and valvular 147 disease, in patients with autoimmune disease⁸. 148 The relationship between valvular disease and IMID has not been fully explored. Recent 149 study suggests there is an increased risk for development of valvular disease in patients with IMID^{8,9,10}. One large population-based study reported non-inferior outcomes in acute mortality 150 151 among IMID patients after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) as compared to those without concomitant IMID¹¹. However, the role 152 153 of auto-immune inflammation on the durability of implanted valves remains unclear. Whether 154 patients with IMID are at risk of early prosthetic valve dysfunction or failure compared to 155 patients without IMID is unknown. We sought to explore this question using longitudinal 156 echocardiographic data to assess differences in development of bioprosthetic valve failure (BVF) 157 after surgical and transcatheter aortic valve replacements between patients with and without 158 IMID.

159 **METHODS**:

160	Patients who underwent TAVR or SAVR at Cleveland Clinic between 2000 and 2022
161	were considered for inclusion. Patients were only included if they had at least 2 echocardiograms
162	in the Cleveland Clinic system available for review after TAVR or SAVR. Patients were
163	included in the IMID group if they had an ICD10 code for autoimmune disease in their chart.
164	These diagnoses included rheumatoid arthritis, psoriasis, vasculitis, polymyalgia rheumatica,
165	Sjogren's, systemic lupus erythematosus, mixed connective tissue disease, and ankylosing
166	spondylitis (supplemental table 1). Patients without ICD10 codes for IMID were considered
167	controls. Patient demographics, comorbidities and medications were extracted from the medical
168	record.
169	Serial echocardiograms performed after aortic valve replacement (AVR) were examined
170	for evidence of bioprosthetic valve failure (BVF) after TAVR or SAVR. Patients were
171	determined to have BVF if they developed one of the following: 1) increase in mean
172	transvalvular gradient of greater than or equal to 20 mmHg resulting in a mean gradient greater
173	than or equal to 30 mmHg when compared with gradients 1 to 3 months post procedure; 2) new
174	occurrence of severe aortic regurgitation not from paravalvular leak; or 3) repeat aortic valve
175	intervention. These criteria were derived from previously published criteria from the VARC3
176	committee ¹² . Post-TAVR echocardiograms with concern for aortic regurgitation were manually
177	reviewed to exclude regurgitation due to paravalvular leak. Echocardiograms performed within
178	the Cleveland Clinic enterprise undergo regular quality assurance to ensure consistency in
179	interpretation. Total follow up time for each patient was determined using the most recent
180	echocardiogram performed after aortic valve replacement.

181	Differences in time to development of BVF after TAVR and SAVR between patients
182	with IMID and without IMID were examined. Patients were included if they developed evidence
183	of BVF at any point after 30 days post-procedure or if they had echocardiogram follow up of at
184	least three years post-procedure. Time to development of BVF was assessed in a univariate
185	capacity with Kaplan-Meier curves using the <i>survfit</i> package in R Version 2023.12.0+369
186	(2023.12.0) as has been previously described ¹³ . Cox proportional hazards regression was used
187	for multivariate analysis to account for differences in age, sex, and medical comorbidities
188	between the groups as been previously described ¹³ . Separate analysis was done in the SAVR and
189	TAVR populations. A Kaplan-Meier curve was generated with both TAVR and SAVR patients
190	to compare overall rates of BVF between groups.
191	
192	
193	
194	
195	
196	
197	
198	
199	
200	
201	
202	
203	

204 **RESULTS**:

205 Bioprosthetic Valve Failure after TAVR:

206 A total of 354 IMID patients and 1202 controls who underwent native valve TAVR at 207 Cleveland Clinic between 2000 and 2022 who had greater than 2 echocardiograms were 208 considered for inclusion in the study. 1,203 (302 IMID and 903 controls) were excluded due to 209 insufficient duration of follow echocardiograms up post TAVR (less than 3 years). 351 TAVR 210 patients (52 IMID and 299 controls) were included in the final analysis (Figure 1A). A higher 211 percentage of IMID patients were excluded compared with controls (302/354 (85.3% excluded)) 212 vs 903/1203 (75.1% excluded); p < 0.001). Mean total follow up times were similar for IMID 213 and controls at 4.1 \pm 1.4 years and 4.3 \pm 1.3 years (p = 0.354), respectively. Medical comorbidities 214 between the IMID and controls were similar, including similar rates of hypertension, 215 hyperlipidemia, chronic kidney disease, coronary artery disease, and atrial fibrillation. Chronic 216 obstructive pulmonary disease and type 2 diabetes were more common in IMID group than 217 controls. Additionally, there were more women in the IMID group (33 (63.5%) vs 114 (38.1%); 218 p < 0.001) and the IMID group was younger relative to the controls (78.1±9.4 years vs 80.1±8.7 219 years; p = 0.017). 220 Medication use and individual autoimmune disease prevalence for IMID patients who

underwent TAVR are displayed in table 1 and 2, respectively. Diagnoses included RA (15,

222 28.8%), psoriasis (12, 23.1%), vasculitis (7, 13.5%), polymyalgia rheumatica (PMR)(7,

223 120213.5%), mixed connective tissue disease (MCTD) (3, 5.8%), SLE (3, 5.8%), Sjogren's

disease (4, 7.7%), and ankylosing spondylitis (1, 1.9%) (Table 2). Due to low sample size, there

225 was insufficient power to detect differences in BVF for individual IMID diagnoses. Rates of

disease-modifying antirheumatic drugs (DMARDs) were predictably higher among IMID

patients (Table 1). There were 8 (15.4%) patients on methotrexate, 14 (26.9%)

hydroxychloroquine, 5 (9.6%) rituximab, 3 (5.8%) leflunomide, and 4 (7.7%) anti-TNF agents
(Table 1).

230	Edwards LifeSciences was the most common manufacturer represented among the
231	cohort. Medtronic, Abbot, Boston Scientific, and Direct Flow represented a small minority of
232	valves present. Edwards Lifesciences valves were less prevalent among IMID compared to
233	controls (43 (82.7%) vs 276 (92.3%); $p = 0.026$) Mean valve size was smaller among IMID
234	patients relative to control patients (24.7 \pm 2.6 vs 25.7 \pm 2.5; p = 0.005) (Table 4).
235	The development of BVF after TAVR was more frequent in patients with IMID when
236	compared with controls. BVF occurred in 12 (23.1%) of IMID patients compared with 21 (7.0%)
237	of controls. Among IMID patients, 5 met BVF criteria due to repeat aortic valve replacement and
238	7 developed BVF due to severely increased gradients. Indication for repeat aortic valve
239	replacement was infective endocarditis (IE) in 4 patients, and severe prosthetic valve aortic
240	regurgitation in 1 patient. One IMID patient developed aortic regurgitation, but upon manual
241	review this was paravalvular leak and was excluded. Among controls, 5 met BVF criteria due to
242	repeat aortic valve intervention and 16 developed BVF due to increased gradients. Indication for
243	repeat aortic valve replacement was IE in 2 patients and severe prosthetic valve stenosis in 3
244	patients. There were 9 patients with evidence of aortic regurgitation, but upon manual review 7
245	had a component of paravalvular leak and were excluded. For consistency, the remaining 2 were
246	excluded in order to have consistent comparisons between IMID and controls within the TAVR
247	comparison.

Development of BVF also occurred significantly earlier in IMID patients compared withcontrols. Figure 2 shows a Kaplan Meier curve demonstrating earlier failure rates in IMID, with

250	estimated time to 50% of IMID developing BVF to be 6.6 years, while this time could not be
251	calculated in controls due to low prevalence of failure ($p < 0.001$) (Figure 2). Differences in
252	development of BVF persisted after multivariate analysis with cox proportional hazard
253	regression. After adjustment for differences in age, sex, and comorbidities between IMID and
254	control group, the adjusted hazard ratio for developing BVF in IMID compared with control was
255	4.02 (CI: $1.81 - 8.92$) (p < 0.001) (Table 3). Development of BVF was also independently
256	associated with increased age and nonwhite race (Table 3).
257	
258	Bioprosthetic valve failure after SAVR:
259 260	There were 443 patients with IMID and 2316 controls who underwent native valve
261	SAVR between 2000 and 2022 with at least 2 consecutive echocardiograms post procedure in the
262	Cleveland Clinic system. Of these, 798 (143 IMID and 655 controls) were excluded due to
263	insufficient follow up time of less than 3 years. A total of 1961 (300 IMID and 1661 controls)
264	were included in the analysis after exclusions. A higher percentage of IMID were excluded
265	relative to controls (143/443 (32.3% excluded) vs 655/2316 (28.3% excluded); p = 0.089).
266	Comorbidities such as HTN, HLD, HLD, CAD, and atrial fibrillation were similar between
267	groups. When comparing IMID to controls, there was more type 2 diabetes (134 (44.7%) vs 598
268	(36.0%); p = 0.004), COPD (131 (43.7%) vs 486 (29.3%); p < 0.001), and women (117 (39.0%)
269	vs 451 (27.2%); p < 0.001). The IMID group was also older, with mean age 69.3 \pm 12.1 years vs
270	66.9 \pm 12.4 years (p = 0.003). Similar to the TAVR analysis, rates of disease-modifying
271	antirheumatic drugs (DMARDs) was predictably higher among IMID patients (Table 1).
272	Medication use and individual autoimmune disease prevalence for IMID patients who
273	underwent SAVR can be seen in table 1 and 2, respectively. Diagnoses included RA 98, 32.7%),

274	psoriasis (65, 21.7%), vasculitis (41, 13.7%), PMR (40, 13.3%), MCTD (17, 5.7%), SLE (17,
275	5.7%), Sjogren's (15, 5.0%), and ankylosing spondylitis (7, 2.3%) (Table 2). There were 52
276	(17.3%) patients on methotrexate, 42 (14.0%) hydroxychloroquine, 9 (3.0%) rituximab, 14
277	(3.0%) leflunomide, 26 (8.7%) anti-TNF agents (Table 1).
278	Bioprosthetic, homograft, and mechanical valve replacements were present in both
279	groups. Bioprosthetic replacement was most common, and homograft and mechanical
280	replacements had similar prevalence (Table 5). Prevalence of each replacement type was similar
281	in IMID compared with control, with bioprosthetic being slightly more prevalent among IMID
282	compared with controls ($p = 0.074$)(Table 5). Manufacturers of each valve type were collected
283	for each group. Among bioprosthetic valves, Edwards Lifesciences and St. Jude Trifecta were
284	the most common manufacturers. Several additional manufacturers made up a small minority of
285	the remainder of the valves, including Cryolife, Medtronic, Perceval, and Sorin. Overall
286	prevalence of each manufacturer for IMID and control valves were similar among bioprosthetic
287	valves ($p = 0.812$)(Table 4). Among mechanical valve replacements, St Jude, Carbomedics, and
288	On-X were present with distribution of individual manufacturers being similar when IMID group
289	is compared to control ($p = 0.942$)(Table 5). Mean valve size was smaller in IMID compared
290	with controls (23.0 \pm 2.3 vs 23.3 \pm 2.4; p = 0.0299).

The mean follow up time in patients who underwent SAVR included for study was 8.9±4.6 years and 9.5±5.3 years for IMID and controls, respectively (p = 0.056). There was no significant difference in the development BVF in the IMID group compared with control. BVF occurred in 59 (19.7%) of IMID patients and in 425 (25.6%) of control patients. Among BVF in IMID patients, 23 had severe aortic regurgitation, 35 had elevated gradients, and one had evidence of both at first detection of BVF. Among controls, 139 had severe aortic regurgitation,

297	265 had elevated gradients, and 21 had evidence of both at first detection of BVF. Multivariable
298	analysis was performed with cox proportional hazard regression. After adjustment for differences
299	in age, sex, and comorbidities between IMID and control group, the adjusted hazard ratio for
300	developing BVF in IMID compared with control was 0.90 (CI: $0.68 - 1.19$) (p = 0.417) (Table
301	3). Additionally, female sex, increased age, and CAD were associated with increased risk of
302	developing BVF independent of IMID status (Table 3). Estimated time to development of BVF
303	after SAVR was also not significantly different, occurring at 16.2 years and 16.0 years in the
304	IMID and control groups, respectively ($p = 0.47$). Kaplan Meier curve demonstrating
305	development of BVF after SAVR over time in both groups is displayed in Figure 3.
306	RA was the most common IMID diagnosis in the SAVR cohort, and a separate analysis
307	was performed to assess development of BVF after SAVR in RA patients only compared to
308	controls. Within the IMID SAVR cohort, there were 98 patients with RA available for study.
309	There was no difference in time to development of BVF after SAVR in in patients with RA
310	compared to patients without RA (Figure 4).
311	
312	Comparing IMID population in TAVR and SAVR:
313	Demographic, medical comorbidities, medication use, and individual diagnoses within
314	patients with IMID who underwent TAVR and SAVR were compared (Table 1)(Table 2).
315	Notably, when compared with SAVR IMID patients, TAVR IMID patients were significantly
316	older (mean age 78.1 \pm 9.4 vs 69.3 \pm 12.1 years; p < 0.001) and contained higher proportion of

- females (33 (63.5%) vs 117 (39.0%); p < 0.001), though the trend of more females in the IMID
- 318 group was the same in both TAVR and SAVR. Comorbidities were similar between groups.
- 319 Prevalence of CAD was similar between groups, but rates of prior myocardial infarction were

320	higher among TAVR patients (18 (34.6%) vs 63 (21.0%); $p = 0.031$). There was significantly
321	higher prevalence of hydroxychloroquine usage among TAVR patients compared with SAVR
322	patients (14 (26.9%) vs 42 (14.0%); p = 0.019) as well as rituximab (5 (9.6%) vs 9 (3.0%); p =
323	0.024). Usage of other DMARDs was similar. Rates of individual autoimmune disease diagnoses
324	were similar between groups (Table 2).
325	Development of BVF occurred earlier in the IMID group in the TAVR cohort but not in
326	the SAVR cohort as discussed above. TAVR cohort members only had bioprosthetic valves,
327	while SAVR cohort members were distributed between bioprosthetic (majority), mechanical, and
328	homografts. In order to assess for confounding of the mechanical and homograft valves in the
329	SAVR cohort, a separate analysis was performed using only the patients who had bioprosthetic
330	valves in the SAVR cohort and comparing this with the TAVR cohort. This generated a Kaplan
331	Meier curve (Figure 5) with both SAVR (bioprosthetic valves only) and TAVR cohorts together.
332	TAVR patients with IMID developed BVF significantly earlier than the rest of the groups.
333	TAVR patients without IMID appear to develop BVF at a similar rate to the SAVR cohort
334	(Figure 5).
335	
336	
337	
338	
339	
340	
341	
342	

343 **DISCUSSION:**

344 To our knowledge, this is the first study to examine bioprosthetic valve function after 345 TAVR and SAVR in patients with IMID. Our results support that patients with IMID who 346 undergo TAVR develop BVF significantly earlier and more frequently relative to patients 347 without IMID. These differences in BVF among IMID patients were not seen after SAVR, but 348 comparisons between the studied TAVR and SAVR populations are limited by the retrospective, 349 observational nature of the study. Prior population-based studies examining outcomes in patients 350 with autoimmune disease after aortic valve replacement have focused on outcomes such as mortality, length of hospital stay, and readmission using broad national databases^{11, 14}. They 351 352 showed similar rates of mortality with the primary conclusion that autoimmune disease should 353 not preclude this patient population from undergoing these procedures. The results of the present 354 study are important, because they suggest IMID patients have different outcomes in prosthetic 355 valve function after TAVR than those without IMID. While IMID should not preclude patients 356 from undergoing these procedures, it may necessitate special consideration in choosing between 357 TAVR or SAVR in these patients. Frequency of follow-up imaging in the IMID patients may 358 also be impacted by these findings.

Notably, the TAVR IMID group was the only group studied with significantly different rates of BVF, and differences in BVF in patients with or without IMID were not observed in the SAVR cohort (Figure 5). The control TAVR group developed BVF at similar rates to all SAVR groups. This is consistent with growing evidence that long term outcomes of TAVR are similar to SAVR¹⁵, and this consistency lends strength to this study.

364 Differences in characteristics between the IMID TAVR and SAVR groups were
365 considered in an attempt to explain this difference in outcomes between AVR methods. Rates of

366	individual IMID diagnoses were similar within the groups, as were majority of medical
367	comorbidities, other than SAVR patients being notably younger. Younger age has consistently
368	been shown to be associated with BVF in prior surgical studies ¹⁶ . The only rheumatologic
369	difference observed between groups was rate of hydroxychloroquine and rituximab utilization.
370	Prevalence of hydroxychloroquine and rituximab in TAVR IMID patients were roughly double
371	that seen in SAVR IMID patients (Table 1). The role of DMARDs in development of
372	cardiovascular disease in patients with autoimmune disease is an area of interest, with many
373	studies suggesting an overall protective effect with increased exposure ^{17, 18} . The differences in
374	medication usage may signal differences in disease severity, which could contribute to
375	differences in outcomes between the TAVR and SAVR groups.
376	Differences in bioprosthetic valve characteristics were also considered as potential
377	confounders in the study, including differences in valve sizes and types between TAVR and
378	SAVR groups. On average, IMID patients had smaller valve size in both TAVR and SAVR
379	compared with controls, likely explained by higher proportion of women in the IMID groups.
380	This trend was similar in both TAVR and SAVR cohorts, however the skew toward women was
381	greater among TAVR. When considered in multivariate analysis with cox regression, male sex
382	appeared protective against BVF in SAVR, but not TAVR. This difference between populations
383	could contribute to the differences in outcomes and larger study with sufficient power for more
384	nuanced matching is warranted in the future.
385	One hypothesis for the development of BVF after TAVR but not SAVR may be related to
386	the mechanism of valvular disease in IMID and the differences in how the aortic valve
387	procedures are performed. The biologic mechanisms of valvular disease from calcification is a
388	result of inflammation from CD4+ T-cell signaling and pro-inflammatory macrophages ^{19, 20, 21, 22} .

389	Studies reporting surgical pathology of aortic stenosis in patients with autoimmune disease show
390	a more inflammatory microscopic profile relative to what is seen in patients without
391	inflammatory disease ^{23, 24} . The excision of the native aortic valve and surrounding tissue during
392	SAVR may be protective against future inflammation and degradation in the prosthetic valve, in
393	contrast to TAVR where the native inflamed tissue remains post procedure. Other potential
394	mechanisms could be related to the hypercoagulable state seen in some IMID. Hypoattenuating
395	leaflet thrombosis, a known complication after SAVR and TAVR with unclear clinical
396	implications ^{25, 26, 27} , was not assessed in the present study but would warrant investigation in
397	future research.
398	Furthermore, IE was more prevalent among IMID patients after TAVR compared with
399	controls. Differences in development of IE were not seen after SAVR. There were 4 IMID
400	patients (7.7%) and 2 control patients (0.7%) who developed IE post TAVR. The mechanism for
401	this difference is unclear. It could be similarly related to the proinflammatory state of IMID as
402	described in the previous paragraph, leaving the bioprosthetic valve at increased vulnerability for
403	seeding with transient bacteremia due to increased inflammation. Alternatively, the
404	immunosuppression used in management of IMID could predispose these patients to IE.
405	However, the 4 IMID patients who developed IE were either on MTX monotherapy (2 patients)
406	or HCQ monotherapy (2 patients) rather than more severe immunosuppression such as rituximab
407	or other biologic agents.
408	The difference in outcomes in the TAVR and SAVR groups has potential significance for
409	IMID patients being considered for AVR. Since FDA approval of TAVR in low-risk surgical
410	patients in 2019, the role of TAVR has been expanded to patients who previously would have

411 been recommended SAVR²⁸. Continued positive results from long term, prospective follow up

such at the NOTION trial¹⁵ will likely continue to increase rates of TAVR. Additionally, 412 413 guidelines recommend "shared decision making" for decision of TAVR vs SAVR in patients age 65 to 80^{29} . The results of the present study suggest patients with IMID in this age window being 414 415 considered for TAVR should be carefully counseled on the potential risk of early BVF. Special 416 considerations may be necessary, such as increased frequency of follow up due to increased risk 417 of early BVF. The potential increased risk for IE in IMID patients should also be considered 418 during shared decision making, and antibiotics for IE prophylaxis should be emphasized in this 419 population. Further study is needed in larger cohorts to validate these findings and make 420 interpopulation assessments between differences in SAVR and TAVR outcomes in patients with IMID. 421 422 This study has limitations. Notably, the rate of valve dysfunction reported here appears higher than previously reported^{15, 30}. This is likely due to the retrospective nature of the study, 423 424 which artificially increases prevalence of BVF since significant patient numbers were excluded 425 due to insufficient follow up. This preferentially excludes patients without valve issues, since 426 sicker patients would be expected to have closer follow-up. Secondly, while the study effectively 427 captured a multitude of IMID diagnoses, disease severity is not readily accounted for in our 428 analysis. It is possible that comorbid IMID disease severity in TAVR patients was greater than in 429 SAVR patients, which could explain the differences seen in development of BVF. Thirdly, due 430 to high rates of exclusion for lack of appropriate follow up, our population of IMID patients is 431 small. The control TAVR and SAVR patients are also a small subset of a larger cohort patients 432 who have undergone aortic valve replacement at Cleveland Clinic. This small size increases 433 potential for both type 1 and type 2 error, and repeat study is warranted in a larger, multicenter 434 population. Lastly, while both TAVR and SAVR populations were studied, limited comparisons

435	between the groups can be made due to the retrospective, observational nature of the study.
436	Further large-scale study is needed to draw conclusions when comparing patients with IMID
437	who undergo SAVR and TAVR.
438	In conclusion, in this single-center, retrospective study, patients with IMID that undergo
439	TAVR develop BVF significantly earlier and more frequently than patients without IMID. Rates
440	of BVF after SAVR were similar between patients with and without IMID. This may have
441	implications for shared decision making in choosing aortic valve interventions for patients with
442	IMID, and warrant increased follow up intervals in IMID patients who undergo TAVR.
443	
444	
445	
446	
447	
448	
449	
450	
451	
452	
453	
454	
ŢJŦ	
455	

456

457 **REFERENCES:**

458	1.	McGonagle D, McDermott MF. A proposed classification of the immunological diseases.
459		PLoS Medicine. 2006;3(8):1242–1248.
460	2.	Polachek, A., Touma, Z., Anderson, M. and Eder, L. (2017), Risk of Cardiovascular
461		Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.
462		Arthritis Care & Research, 69: 67-74. https://doi.org/10.1002/acr.22926
463	3.	Gonzalez A, Kremers HM, Crowson CS, et al. Do cardiovascular risk factors confer the
464		same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-
465		rheumatoid arthritis patients? Annals of the Rheumatic Diseases 2008;67:64-69.
466	4.	Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel
467		SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM. Risk of major cardiovascular events in
468		patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based
469		cohort study. Ann Rheum Dis. 2015 Feb;74(2):326-32. doi: 10.1136/annrheumdis-2014-
470		205675. Epub 2014 Oct 28. PMID: 25351522; PMCID: PMC4341911.
471	5.	Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated
472		inflammatory diseases: recommendations for clinical practice. Heart. 2022 Jan;108(1):73-
473		79. doi: 10.1136/heartjnl-2019-316378. Epub 2021 Mar 4. PMID: 33674356; PMCID:
474		PMC8666803.
475	6.	Ajeganova S, Hafström I, Frostegård J. Patients with SLE have higher risk of
476		cardiovascular events and mortality in comparison with controls with the same levels of
477		traditional risk factors and intima-media measures, which is related to accumulated
478		disease damage and antiphospholipid syndrome: A case-control study over 10 years.
479		Lupus Science and Medicine. 2021;8(1):1–11.

480	7.	Peters, M.J., et al., Does rheumatoid arthritis equal diabetes mellitus as an independent
481		risk factor for cardiovascular disease? A prospective study. Arthritis Rheum, 2009.
482		61 (11): p. 1571-9.
483	8.	Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G,
484		Mason JC, Rahimi K, McMurray JJV, Verbakel JY. Autoimmune diseases and
485		cardiovascular risk: a population-based study on 19 autoimmune diseases and 12
486		cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022 Sep
487		3;400(10354):733-743. doi: 10.1016/S0140-6736(22)01349-6. Epub 2022 Aug 27.
488		PMID: 36041475.
489	9.	Johnson TM, Mahabir CA, Yang Y, et al. Aortic Stenosis Risk in Rheumatoid
490		Arthritis. JAMA Intern Med. 2023;183(9):973–981.
491		doi:10.1001/jamainternmed.2023.3087
492	10	. Ward MM. Lifetime risks of valvular heart disease and pacemaker use in patients with
493		ankylosing spondylitis. Journal of the American Heart Association. 2018;7(20).
494	11.	. Gad MM, Lichtman D, Saad AM, Isogai T, Bansal A, Abdallah MS, Roselli E, Chatterjee
495		S, Reed GW, Kapadia SR, Menon V, Wassif H. Autoimmune connective tissue diseases
496		and aortic valve replacement outcomes: a population-based study. European Heart
497		Journal Open. 2022;2(3):1–14.
498	12	. Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke
499		P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, et al. Valve
500		Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve
501		Clinical Research. Journal of the American College of Cardiology. 2021;77(21):2717–
502		2746.

503	13. Arthur Allignol, Aurelien Latouche (2023). CRAN Task View: Survival Analysis.
504	Version 2023-09-10. URL https://CRAN.R-project.org/view=Survival.
505	14. Rudasill SE, Sanaiha Y, Xing H, Mardock AL, Khoury H, Jaman R, Ebrahimi R,
506	Benharash P. Association of Autoimmune Connective Tissue Disease and Outcomes in
507	Patients Undergoing Transcatheter Aortic Valve Implantation. American Journal of
508	Cardiology. 2019;123(10):1675–1680.
509	15. Thyregod HGH, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ,
510	Petursson P, De Backer O, Olsen PS, Søndergaard L. Transcatheter or surgical aortic
511	valve implantation: 10-year outcomes of the NOTION trial. European Heart Journal.
512	2024:1–9.
513	16. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, Smedira NG,
514	Svensson LG, Lytle BW, Blackstone EH. Long-term durability of bioprosthetic aortic
515	valves: implications from 12,569 implants. Ann Thorac Surg. 2015 Apr;99(4):1239-47.
516	17. Baoqi Y, Dan M, Xingxing Z, Xueqing Z, Yajing W, Ke X, Liyun Z. Effect of Anti-
517	Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis. Frontiers
518	in Cardiovascular Medicine. 2022;8(February):1–13.
519	18. Yates M, Iftikhar Talib A, Aldus C, Brown J, Macgregor A. Pos0321 Co-Morbidity in
520	Polymyalgia Rheumatica. Annals of the Rheumatic Diseases. 2022;81(Suppl 1):411.2-
521	412.
522	19. Breed ER, Binstadt BA. Autoimmune valvular carditis. Curr Allergy Asthma Rep.
523	2015;15(1):491. doi:10.1007/s11882-014-0491-z
524	20. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the
525	early lesion of 'degenerative' valvular aortic stenosis. Histological and

immunohistochemical studies. Circulation. 1994;90(2):844-53. Epub 1994/08/01.

527	pmid:7519131.
528	21. Mohler ER 3rd, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of
529	osteopontin in calcified human aortic valves. Arteriosclerosis, thrombosis, and vascular
530	biology. 1997;17(3):547-52. Epub 1997/03/01. pmid:9102175.
531	22. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, et al.
532	Osteopontin is expressed in human aortic valvular lesions. Circulation. 1995;92(8):2163-
533	8. Epub 1995/10/15. pmid:7554197.
534	23. Peyrou J, Saxer-Sekulic N, Lerch R, Müller H. Fast progression of aortic stenosis in
535	rheumatoid arthritis. Archives of Cardiovascular Diseases. 2009;102(3):251-252.
536	24. Bridge K, Farivar RS. A case of Sjögren's syndrome leading to mitral and aortic valve
537	replacement. Journal of Thoracic and Cardiovascular Surgery. 2010;139(6):e139-e140.
538	25. Garcia S, Fukui M, Dworak MW, et al. Clinical Impact of Hypoattenuating Leaflet
539	Thickening After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular
540	Interventions. 2022;15(3):e011480. doi:10.1161/CIRCINTERVENTIONS.121.011480
541	26. Hein M, Schoechlin S, Schulz U, et al. Long-Term Follow-Up of Hypoattenuated Leaflet
542	Thickening After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular
543	Interventions. 2022;15(11):1113-1122. doi:10.1016/j.jcin.2022.04.018
544	27. Sondergaard L, De Backer O, Kofoed KF, Jilaihawi H, Fuchs A, Chakravarty T, Kashif
545	M, Kazuno Y, Kawamori H, Maeno Y, Bieliauskas G, Guo H, Stone GW, Makkar R.
546	Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic
547	valves. Eur Heart J. 2017;38(28):2201-2207.

-						
510	28 Could	wright M. Forr	act IK McCab	a IM Nazif TM	TAVP in Low	Pick Dationter FDA
J40	20.0000	5WH2IIU WI. FUH	zsi jin. Miceau	C JIVI. INAZII I IVI		-NISK I dubilis. I DA

- 549 Approval, the New NCD, and Shared Decision-Making. *Journal of the American College*
- *of Cardiology*. 2020;75(10):1208–1211.
- 551 29. Otto CM, Nishimura RA, Bonow RO, Carabello BA, rwin JP, Gentile F, Jneid H, Krieger
- ric V., Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C.
- 553 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease:
- 554 A Report of the American College of Cardiology/American Heart Association Joint
- 555 *Committee on Clinical Practice Guidelines.*; 2021.
- 30. Barbanti M, Costa G, Zappulla P, Todaro D, Picci A, Rapisarda G, Di Simone E, Sicuso
- 557 R, Buccheri S, Gulino S, Pilato G, Spina K La, D'Arrigo P, Valvo R, Indelicato A, et al.
- 558 Incidence of long-term structural valve dysfunction and bioprosthetic valve failure after
- transcatheter aortic valve replacement. *Journal of the American Heart Association*.
- 560 2018;7(15):1–10.
- 561
- 562
- 563
- 564
- 565
- 566
- 567
- 568
- 569



Flow chart delineating inclusion exclusion process for TAVR patients for Figure 1A. assessment of BVF *TAVR=transcatheter aortic valve replacement; IMID=immune mediated inflammatory disease; BVF=bioprosthetic valve failure; AVR=aortic valve replacement*



583 Figure 1B. Flow chart delineating inclusion exclusion process SAVR patients for assessment of BVF

- 585 SAVR=surgical aortic valve replacement; BVF=bioprosthetic valve failure; IMID=immune
- 586 *mediated inflammatory disease; AR=aortic regurgitation*





Figure 3. Kaplan Meier curve assessing development of BVF after SAVR in patients with andwithout IMID

```
606 IMID=immune mediated inflammatory disease; SAVR=surgical aortic valve replacement;
```

BVF=bioprosthetic valve failure



Time to Bioprosthetic Valve Failure after SAVR in RA

Figure 4. Kaplan Meier curve assessing development of BVF after SAVR in patients withand without Rheumatoid Arthritis

RA=rheumatoid arthritis; SAVR=surgical aortic valve replacement; BVF=bioprosthetic valve failure

- 622 j



Time to Bioprosthetic Valve Failure after SAVR or TAVR

649 SAVR=surgical aortic valve replacement; TAVR=Transcatheter aortic valve replacement;
 650 IMID=immune mediate inflammatory disease; BVF=bioprosthetic valve failure; AVR=Aortic

valve replacement

		TAVR			SAVR		IMID ir	n TAVR vs SAV	R
	IMID	Control	P-value	IMID	Control	P-value	IMID TAVR	IMID SAVR	P-value
	(n= 52)	(n = 299)		(n = 300)	(n = 1661)		(n = 52)	(n = 300)	
Age, mean (SD)	78.1 (9.4)	80.1 (8.7)	0.017	69.3 (12.1)	66.9 (12.4)	0.003	78.1 (9.4)	69.3 (12.1)	<0.001
Female, n (%)	33 (63.5%)	114 (38.1%)	<0.001	117 (39.0%)	451 (27.2%)	<0.001	33 (63.5%)	117 (39.0%)	<0.001
Race, n (%)									
White	49 (94.2%)	275 (91.9%)	0.678	281 (93.7%)	1510 (90.9%)	0.284	49 (94.2%)	281 (93.7%)	0.391
Black	3 (5.8%)	20 (6.7%)		11 (3.7%)	93 (5.6%)		3 (5.8%)	11 (3.7%)	
Other	0	4 (1.3%)		8 (2.7%)	58 (3.5%)		0	8 (2.7%)	
Hypertension, n (%)	51 (98.1%)	289 (96.7%)	0.587	283 (94.3%)	1547 (93.1%)	0.445	51 (98.1%)	283 (94.3%)	0.258
Hyperlipidemia, n (%)	51 (98.1%)	277 (92.7%)	0.144	269 (89.7%)	1442 (86.8%)	0.173	51 (98.1%)	269 (89.7%)	0.052
COPD, n (%)	27 (51.9%)	112 (37.5%)	0.049	134 (44.7%)	486 (29.3%)	< 0.001	27 (51.9%)	134 (44.7%)	0.332
Type 2 Diabetes, n (%)	27 (51.9%)	111 (37.1%)	0.043	134 (44.7%)	598 (36.0%)	0.004	27 (51.9%)	134 (44.7%)	0.332
CKD, n (%)	26 (50.0%)	151 (50.5%)	0.947	124 (41.3%)	589 (35.5%)	0.052	26 (50.0%)	124 (41.3%)	0.243
CAD, n (%)	26 (50.0%)	161 (53.8%)	0.608	154 (51.3%)	817 (49.2%)	0.494	26 (50.0%)	154 (51.3%)	0.859
MI	18 (34.6%)	83 (27.8%)	0.313	63 (21.0%)	300 (18.1%)	0.228	18 (34.6%)	63 (21.0%)	0.031
PCI	8 (15.4%)	79 (26.4%)	0.089	32 (10.7%)	181 (10.9%)	0.906	8 (15.4%)	32 (10.7%)	0.322
CABG	11 (21.2%)	99 (33.1%)	0.086	122 (40.7%)	677 (40.8%)	0.976	11 (21.2%)	122 (40.7%)	0.007
Atrial Fibrillation, n (%)	32 (61.5%)	173 (57.9%)	0.619	194 (64.7%)	1039 (62.6%)	0.485	32 (61.5%)	194 (64.7%)	0.664
Tobacco Use, n (%)	27 (51.9%)	185 (61.9%)	0.176	177 (59.0%)	1002 (60.3%)	0.666	27 (51.9%)	177 (59.0%)	0.339
Medications, n (%)									
ARNI	2 (3.8%)	27 (9.0%)	0.211	6 (2.0%)	75 (4.5%)	0.044	2 (3.8%)	6 (2.0%)	0.411
SGLT2	9 (17.3%)	27 (9.0%)	0.069	23 (7.7%)	119 (7.2%)	0.757	9 (17.3%)	23 (7.7%)	0.026
Digoxin	13 (25.0%)	40 (13.4%)	0.031	57 (19.0%)	268 (16.1%)	0.219	13 (25.0%)	57 (19.0%)	0.317
Methotrexate	8 (15.4%)	1 (0.3%)	<0.001	52 (17.3%)	7 (0.4%)	<0.001	8 (15.4%)	52 (17.3%)	0.731
Hydroxychloroquine	14 (26.9%)	0	<0.001	42 (14.0%)	10 (0.6%)	<0.001	14 (26.9%)	42 (14.0%)	0.019
Rituximab	5 (9.6%)	1 (0.3%)	<0.001	9 (3.0%)	0	<0.001	5 (9.6%)	9 (3.0%)	0.024
Leflunimide	3 (5.8%)	0	<0.001	14 (4.7%)	0	<0.001	3 (5.8%)	14 (4.7%)	0.732
Anti-TNF	4 (7.7%)	0	<0.001	26 (8.7%)	9 (0.5%)	<0.001	4 (7.7%)	26 (8.7%)	0.816

Table 1.Demographics, comorbidities, and medication usage of patients with and without
IMID undergoing TAVR and SAVR

P values for TAVR and SAVR are comparing characteristics of IMID versus controls. The third
column is comparing the IMID groups between TAVR and SAVR cohorts

TAVR=transcatheter aortic valve replacement; SAVR=Surgical aortic valve replacement;

IMID=Immune mediated inflammatory disease; SD=standard deviation; COPD=chronic

obstructive pulmonary disease; CKD=chronic kidney disease; CAD=coronary artery disease;

MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery

673 bypass graft; ARNI=angiotensin receptor/neprilysin inhibitor; SGLT2=sodium glucose

transporter inhibitor

Disease, n (%)	TAVR (n =52)	SAVR (n=300)	P - value
Rheumatoid Arthritis	15 (28.8%)	98 (32.7%)	0.586
SLE	3 (5.8%)	17 (5.7%)	0.976
Sjogren's	4 (7.7%)	15 (5.0%)	0.428
PMR	7 (13.5%)	40 (13.3%)	0.968
Vasculitis	7 (13.5%)	41 (13.6%)	0.728
Mixed Connective	3 (5.8%)	17 (5.7%)	0.976
Tissue Disease			
Psoriasis	12 (23.1%)	65 (21.7%)	0.821
Ankylosing Spondylitis	1 (1.9%)	7 (2.3%	0.855

Table 2.Prevalence of individual autoimmune diagnoses in TAVR and SAVR cohort

P value determined in assessing the difference in distribution of each individual diagnosis
 between the TAVR and SAVR cohort

SLE=systemic lupus erythematous; PMR=polymyalgia rheumatica; TAVR=Transcatheter aortic valve replacement; SAVR=surgical aortic valve replacement

	TAVR		SAVR		
	AHR (95% CI)	P-value	AHR (95% CI)	p-value	
IMID	4.02 (1.81 - 8.92)	6.15E-04	0.90 (0.68-1.19)	0.477	
Male Sex	0.97 (0.45-2.07)	0.932	0.75 (0.59-0.88)	0.005	
White Race	0.32 (0.12 – 0.91	0.032	0.74 (0.53-0.97)	0.061	
Age	0.97 (0.94 – 0.99)	0.042	0.98 (0.97-0.99)	7.48E-06	
Hypertension	1.36 (0.18 - 10.43)	0.767	1.26 (0.79-1.62)	0.224	
Hyperlipidemia	0.73 (0.22 – 2.40)	0.601	0.72 (0.54-0.91)	0.012	
COPD	0.56 (0.25 – 1.24)	0.155	1.11 (0.91-1.34)	0.294	
Type 2 Diabetes	0.81 (0.37 – 1.81)	0.597	1.11 (0.89-1.32)	0.301	
Chronic Kidney Disease	1.16 (0.55 – 2.48)	0.687	1.10 (0.90-1.34)	0.384	
Atrial Fibrillation	0.89 (0.43 – 1.86)	0.768	1.12 (0.91-1.33)	0.329	
Coronary Artery Disease	0.65 (0.29 - 1.41)	0.277	1.30 (1.07-1.58)	0.009	

Table 3. Risk factors for developing BVF after TAVR and SAVR

Adjusted hazards ratios generated using cox proportional hazards regression in multivariate fashion

IMID=immune mediated inflammatory disease; TAVR=transcatheter aortic valve replacement;

SAVR=surgical aortic valve replacement; AHR=adjusted hazard ratio; COPD=chronic

obstructive pulmonary disease

	IMID (n = 52)	Control $(n = 299)$	P value	
Valve Size (mm), mean (SD)	24.7 (2.6)	25.7 (2.5)	0.005	
Valve Manufacturer				
Edwards Lifesciences	43 (82.7%)	276 (92.3%)		
Sapien 3	41 (76.9%)	271 (90.6%)	0.026	
Sapien XT	2 (3.8%)	3 (1.0%)		
Sapien Ultra	0	2 (0.6%)		
Other	9 (17.3%)	23 (7.7%)		
Medtronic	7 (13.4%)	12 (4.0%)		
Boston Scientific	1 (1.9%)	4 (1.3%)		
Direct Flow	1 (1.9%)	6 (2.0%)		
Abbot	0	1 (0.3%)		

Table 4.Characteristics of aortic valves used in transcatheter aortic valve replacements
among patients with and without IMID

P value assess distribution between Edwards Lifesciences, Medtronic, and Other manufacturers.
Valve types in italics below Edwards Lifesciences and Other are subsets of those categories
included in the total

IMID=Immune mediated inflammatory disease; SD=Standard deviation

	IMID $(n = 300)$	Control (n = 1661)	P-value	
Valve Size, mean (SD)	23.0 (2.3)	23.3 (2.4)	0.0299	
Valve Type, n (%)				
Bioprosthetic	272 (90.7%)	1426 (85.9%)	0.071	
Mechanical	11 (3.7%)	105 (6.3%)	0.071	
Homograft	17 (5.7%)	130 (7.8%)		
Valve Manufacturer, n (%)				
Bioprosthetic	272 (100%)	1426 (100%)		
Edwards	204 (75.0%)	1075 (75.4%)	0.812	
St Jude	58 (21.3%)	309 (21.7%)		
Other	10 (3.7%)	42 (2.9%)		
Cryolife	0 (0%)	1 (0.1%)		
Medtronic	4 (1.5%)	8 (0.6%)		
Perceval	2 (0.7%)	27 (1.9%)		
Sorin	4 (1.5%)	6 (0.4%)		
Mechanical	11 (100%)	105 (100%)		
St Jude	6 (54.5%)	52 (49.5%)	0.042	
Carbomedics	3 (27.3%)	30 (28.6%)	0.942	
On-X	2 (18.2%)	23 (21.9%)		

Table 5.Characteristics of aortic valves used in surgical aortic valve replacements among
patients with and without IMID

P values compare total distribution of BP, mechanical, and homograft valves as well as the

distribution of types of valves within the bioprosthetic and mechanical subsets

IMID=immune mediate inflammatory disease; SD=standard deviation;